Investments
53Portfolio Exits
3
Want to inform investors similar to DYEE Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest DYEE Capital News
Sep 29, 2020
InventisBio , a Shangai, China-based clinical stage biotech company dedicated to the research and development of innovative small molecule drugs, closed a $147m series D financing. The was led by Hillhouse affiliate GL Ventures, followed by Qiming Venture Partners, Janchor, AIHC Capital, Matrix Partner China, Dyee Capital, E Fund Capital and other investors. The existing shareholders including Lilly Asia Venture, OrbiMed Asia, Pudong Innotek, AdvanTech Capital, and CMB International continued their support. Led by Dr. Yaolin Wang, Chairman and CEO, InventisBio is an innovative biotech company that focuses on the research and development of proprietary small molecule drugs for the treatment of cancer and metabolic diseases. Currently, InventisBio has three drug products in the mid- to late-stage clinical development, and one new product just entered global phase I clinical study. Among them, D-0502 is an oral selective estrogen receptor degrader (SERD), which also acts as an estrogen receptor antagonist, with therapeutic potential for the treatment of hormone receptor positive breast cancer. In addition, the company has independently developed a third-generation EGFR-T790M tyrosine kinase inhibitor BPI-D0316 and out-licensed China right to Betta Pharma. This product is currently in registration trials of first- and second-line treatment of EGFR-mutated non-small cell lung cancer patients and the trials are progressing fast. Funds raised in this round will be mainly used to support the company’s current products into phase II clinical studies in China and the United States, including D-0502 trials in hormone receptor positive breast cancer and D-0120 trials in gout. This round will also support the company’s global clinical development of other new drugs, enable further expansion of the company’s product pipeline and team. FinSMEs 29/09/2020
DYEE Capital Investments
53 Investments
DYEE Capital has made 53 investments. Their latest investment was in Genepoint Biological Technology as part of their Series D on January 1, 2023.
DYEE Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
1/18/2023 | Series D | Genepoint Biological Technology | $29.6M | No | 2 | |
11/4/2022 | Series D | Welion | $206.1M | Yes | 6 | |
10/20/2022 | Series C - II | MaxiNovel | $13.86M | No | 4 | |
8/5/2022 | Series B | |||||
7/27/2022 | Series B |
Date | 1/18/2023 | 11/4/2022 | 10/20/2022 | 8/5/2022 | 7/27/2022 |
|---|---|---|---|---|---|
Round | Series D | Series D | Series C - II | Series B | Series B |
Company | Genepoint Biological Technology | Welion | MaxiNovel | ||
Amount | $29.6M | $206.1M | $13.86M | ||
New? | No | Yes | No | ||
Co-Investors | |||||
Sources | 2 | 6 | 4 |
DYEE Capital Portfolio Exits
3 Portfolio Exits
DYEE Capital has 3 portfolio exits. Their latest portfolio exit was InventisBio on July 25, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
7/25/2022 | IPO | Public | 1 | ||
Date | 7/25/2022 | ||
|---|---|---|---|
Exit | IPO | ||
Companies | |||
Valuation | |||
Acquirer | Public | ||
Sources | 1 |
DYEE Capital Team
1 Team Member
DYEE Capital has 1 team member, including current Managing Director, Dezhen Zhu.
Name | Work History | Title | Status |
|---|---|---|---|
Dezhen Zhu | Managing Director | Current |
Name | Dezhen Zhu |
|---|---|
Work History | |
Title | Managing Director |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.